Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NP2GO vs ShedRx

NP2GO
Graded #23Editorial

Lower grade

vs+8
ShedRx
Graded #3Partner

Higher grade

The verdict

ShedRx takes it — 88/100 to 80/100.

ShedRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The widest formulation spread on the board — oral/sublingual routes plus standard injection.

Partner links are labeled — we may earn a commission at no cost to you. It never changes the grade.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueShedRx +5
81
86
Dose & formulationShedRx +15
80
95
Clinical oversightShedRx +5
79
84
Labs & monitoringShedRx +6
78
84
FulfillmentShedRx +6
82
88
Contract termsShedRx +7
82
89
NP2GO · left barShedRx · right bar

The numbers

MetricNP2GOShedRx
WeighScore80/10088/100
GradeB−B+
Scorecard rank#23#3
Semaglutide$150/mo$199/mo
Tirzepatide$250/mo$299/mo
Coverage40 statesNot disclosed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
RelationshipEditorialPartner
NP2GO

Graded #23 · B−

Strengths

  • Both molecules
  • 40-state footprint
  • Transparent listed pricing

Where it loses points

  • Not LegitScript-verified
  • Upper-mid pricing ($150/$250)
  • Not all 50 states
ShedRx

Graded #3 · B+

Strengths

  • Oral/sublingual options
  • Competitive tirzepatide pricing
  • Strong dose flexibility

Where it loses points

  • States-served not disclosed
  • Compounded only

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard